Finance

Lists
IRLA:NASDAQ
IRulya Therapeutics Inc
$32.96
+1.48%
(+0.48) 1D
$32.24
-2.17% (-0.72)
After hours
Closed: Oct 28, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IRLA...
Open
$32.32
High
$33.40
Low
$31.00
Mkt. cap
357.23M
Avg. vol.
40.68K
Volume
0.00
52-wk high
$40.98
52-wk low
$25.50
EPS
-$125.71
Beta
1.33
Shares outstanding
1.02M
No. of employees
38
Open
$32.32
High
$33.40
Low
$31.00
Mkt. cap
357.23M
Avg. vol.
40.68K
Volume
0.00
52-wk high
$40.98
52-wk low
$25.50
EPS
-$125.71
Beta
1.33
Shares outstanding
1.02M
No. of employees
38
News stories
From web sources and news partners
About IRulya Therapeutics Inc
CEO-
Employees38
Founded2012
HeadquartersSouth San Francisco, California, United States
SectorBiotechnology
Websiteirulya.com
Analyst ratings
Based on 8 analysts giving stock ratings to IRLA in the past 3 months
Strong buy
Buy
8
Hold
0
Sell
0
12-month forecast
Based on 8 Wall Street analysts offering 12 month price targets for IRLA in the last 3 months.
Highest
Current $32.96
$98.00 (+197.38%)
Average
$75.63 (+129.49%)
Lowest
$68.00 (+106.34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Tiago Fauth
Raymond James
Buy
Initiated
$72.00
+118.5%
10/09/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$98.00
+197.4%
09/30/2026
Joseph Schwartz
Leerink Partners
Buy
Reiterated
$68.00
+106.3%
09/29/2026
Albert Lowe
Craig-Hallum
Buy
Maintained
$68.00
+106.3%
09/30/2026
Seema Sheoran
Rodman & Renshaw
Buy
Initiated
$70.00
+112.4%
09/24/2026
Jonathan Wolleben
Citizens JMP
Buy
Upgraded
$77.00
+133.7%
09/22/2026
Olivia Brayer
Cantor Fitzgerald
Buy
Reiterated
$70.00
+112.4%
08/17/2026
Mazahir Alimohamed
Oppenheimer
Buy
Reiterated
$82.00
+148.8%
08/17/2026
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
8.08M
12.60M
6.84M
5.46M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.28M
3.64M
4.27M
16.63M
Operating expense
11.36M
16.24M
11.11M
22.09M
Total operating expenses
11.36M
16.24M
11.11M
22.09M
Operating income
-11.36M
-16.24M
-11.11M
-22.09M
Other non operating income
191.00K
-17.12M
32.84M
3.78M
EBT including unusual items
-13.49M
-36.31M
30.57M
-75.41M
EBT excluding unusual items
-10.87M
-32.65M
21.88M
-17.72M
Income tax expense
-46.00K
3.15M
-5.34M
75.00K
Effective tax rate
0.34%
-8.66%
-17.46%
-0.10%
Other operating expenses
-
-
-
-
Net income
-13.44M
-39.46M
35.91M
-75.49M
Net profit margin
-
-
-
-
Earnings per share
-50.00
-152.00
57.60
-12.15
Interest and investment income
300.00K
227.00K
160.00K
584.00K
Interest expense
-
-
-
-
Net interest expenses
300.00K
227.00K
160.00K
584.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-11.33M
-16.20M
-11.08M
-22.05M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
Google apps